Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
RVP vs NNBR vs MMSI vs UTMD vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Conglomerates
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
RVP vs NNBR vs MMSI vs UTMD vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Conglomerates | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $21M | $139M | $3.72B | $210M | $1.92B |
| Revenue (TTM) | $38M | $435M | $1.54B | $39M | $674M |
| Net Income (TTM) | $-9M | $-35M | $139M | $11M | $-173M |
| Gross Margin | -6.9% | 2.3% | 48.7% | 52.9% | 75.2% |
| Operating Margin | -58.1% | -3.3% | 12.2% | 29.6% | -27.2% |
| Forward P/E | — | 43.6x | 15.5x | 10.4x | — |
| Total Debt | $1M | $211M | $898M | $225K | $290M |
| Cash & Equiv. | $4M | $11M | $449M | $86M | $103M |
RVP vs NNBR vs MMSI vs UTMD vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Retractable Technol… (RVP) | 100 | 13.0 | -87.0% |
| NN, Inc. (NNBR) | 100 | 61.7 | -38.3% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Utah Medical Produc… (UTMD) | 100 | 65.7 | -34.3% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RVP vs NNBR vs MMSI vs UTMD vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RVP lags the leaders in this set but could rank higher in a more targeted comparison.
NNBR is the #2 pick in this set and the best alternative if momentum is your priority.
- +50.8% vs MMSI's -33.8%
MMSI ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 11.7%, EPS growth 4.9%, 3Y rev CAGR 9.6%
- 214.6% 10Y total return vs UTMD's 19.1%
- 11.7% revenue growth vs RVP's -24.2%
UTMD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 3 yrs, beta 0.55, yield 1.9%
- Lower volatility, beta 0.55, Low D/E 0.2%, current ratio 37.62x
- Beta 0.55, yield 1.9%, current ratio 37.62x
- Better valuation composite
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.7% revenue growth vs RVP's -24.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 29.3% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.55 vs NVCR's 2.20, lower leverage | |
| Dividends | 1.9% yield, 3-year raise streak, vs RVP's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +50.8% vs MMSI's -33.8% | |
| Efficiency (ROA) | 9.3% ROA vs NVCR's -16.5%, ROIC 25.0% vs -16.4% |
RVP vs NNBR vs MMSI vs UTMD vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
RVP vs NNBR vs MMSI vs UTMD vs NVCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UTMD leads in 4 of 6 categories
NNBR leads 1 • RVP leads 0 • MMSI leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UTMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MMSI is the larger business by revenue, generating $1.5B annually — 40.4x RVP's $38M. UTMD is the more profitable business, keeping 29.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, RVP holds the edge at +73.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $38M | $435M | $1.5B | $39M | $674M |
| EBITDAEarnings before interest/tax | -$15M | $22M | $290M | $14M | -$165M |
| Net IncomeAfter-tax profit | -$9M | -$35M | $139M | $11M | -$173M |
| Free Cash FlowCash after capex | -$14M | -$1M | $274M | $14M | -$48M |
| Gross MarginGross profit ÷ Revenue | -6.9% | +2.3% | +48.7% | +52.9% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -58.1% | -3.3% | +12.2% | +29.6% | -27.2% |
| Net MarginNet income ÷ Revenue | -22.9% | -8.0% | +9.0% | +29.3% | -25.7% |
| FCF MarginFCF ÷ Revenue | -35.5% | -0.3% | +17.8% | +37.2% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +73.2% | +12.1% | +7.8% | -1.2% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.0% | -8.7% | +38.8% | -7.0% | -100.0% |
Valuation Metrics
UTMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 18.8x trailing earnings, UTMD trades at a 36% valuation discount to MMSI's 29.3x P/E. On an enterprise value basis, UTMD's 8.6x EV/EBITDA is more attractive than NNBR's 19.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $21M | $139M | $3.7B | $210M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $18M | $338M | $4.2B | $124M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.76x | -2.58x | 29.26x | 18.79x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.60x | 15.46x | 10.41x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 5.48x | — |
| EV / EBITDAEnterprise value multiple | — | 19.03x | 13.06x | 8.64x | — |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 0.33x | 2.45x | 5.44x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.24x | 0.93x | 2.38x | 1.78x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | 19.16x | 17.24x | 14.63x | — |
Profitability & Efficiency
UTMD leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
UTMD delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-51 for NVCR. UTMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NNBR's 1.44x. On the Piotroski fundamental quality scale (0–9), MMSI scores 6/9 vs NNBR's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -11.4% | -28.4% | +8.9% | +9.6% | -50.8% |
| ROA (TTM)Return on assets | -5.9% | -7.7% | +5.2% | +9.3% | -16.5% |
| ROICReturn on invested capital | -18.4% | -4.5% | +7.2% | +25.0% | -16.4% |
| ROCEReturn on capital employed | -13.1% | -5.0% | +7.9% | +9.6% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 1.44x | 0.57x | 0.00x | 0.85x |
| Net DebtTotal debt minus cash | -$3M | $200M | $450M | -$86M | $187M |
| Cash & Equiv.Liquid assets | $4M | $11M | $449M | $86M | $103M |
| Total DebtShort + long-term debt | $1M | $211M | $898M | $225,000 | $290M |
| Interest CoverageEBIT ÷ Interest expense | -81.41x | -0.74x | 10.74x | — | -96.80x |
Total Returns (Dividends Reinvested)
NNBR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MMSI five years ago would be worth $9,644 today (with dividends reinvested), compared to $712 for RVP. Over the past 12 months, NNBR leads with a +50.8% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors NNBR at 40.7% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.2% | +106.0% | -27.9% | +16.3% | +28.3% |
| 1-Year ReturnPast 12 months | -6.3% | +50.8% | -33.8% | +23.5% | +1.1% |
| 3-Year ReturnCumulative with dividends | -55.4% | +178.4% | -26.5% | -26.2% | -75.7% |
| 5-Year ReturnCumulative with dividends | -92.9% | -63.4% | -3.6% | -18.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -69.9% | -75.7% | +214.6% | +19.1% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -23.6% | +40.7% | -9.8% | -9.7% | -37.6% |
Risk & Volatility
Evenly matched — NNBR and UTMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
UTMD is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NNBR currently trades 92.3% from its 52-week high vs RVP's 61.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 2.04x | 0.71x | 0.55x | 2.20x |
| 52-Week HighHighest price in past year | $1.14 | $2.99 | $100.19 | $71.81 | $20.06 |
| 52-Week LowLowest price in past year | $0.60 | $1.10 | $59.74 | $52.00 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +61.8% | +92.3% | +62.2% | +91.1% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 55.3 | 65.6 | 34.9 | 41.9 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 57K | 936K | 769K | 13K | 1.5M |
Analyst Outlook
UTMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NNBR as "Buy", MMSI as "Buy", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 52.4% for MMSI (target: $95). For income investors, UTMD offers the higher dividend yield at 1.88% vs RVP's 1.09%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | — | $95.00 | — | $33.50 |
| # AnalystsCovering analysts | — | 9 | 13 | — | 15 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | — | — | +1.9% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | 3 | — |
| Dividend / ShareAnnual DPS | $0.01 | — | — | $1.23 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.0% | 0.0% |
UTMD leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). NNBR leads in 1 (Total Returns). 1 tied.
RVP vs NNBR vs MMSI vs UTMD vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RVP or NNBR or MMSI or UTMD or NVCR a better buy right now?
For growth investors, Merit Medical Systems, Inc.
(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus -24. 2% for Retractable Technologies, Inc. (RVP). Utah Medical Products, Inc. (UTMD) offers the better valuation at 18. 8x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate NN, Inc. (NNBR) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RVP or NNBR or MMSI or UTMD or NVCR?
On trailing P/E, Utah Medical Products, Inc.
(UTMD) is the cheapest at 18. 8x versus Merit Medical Systems, Inc. at 29. 3x. On forward P/E, Utah Medical Products, Inc. is actually cheaper at 10. 4x.
03Which is the better long-term investment — RVP or NNBR or MMSI or UTMD or NVCR?
Over the past 5 years, Merit Medical Systems, Inc.
(MMSI) delivered a total return of -3. 6%, compared to -92. 9% for Retractable Technologies, Inc. (RVP). Over 10 years, the gap is even starker: MMSI returned +214. 6% versus NNBR's -75. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RVP or NNBR or MMSI or UTMD or NVCR?
By beta (market sensitivity over 5 years), Utah Medical Products, Inc.
(UTMD) is the lower-risk stock at 0. 55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 298% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 144% for NN, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RVP or NNBR or MMSI or UTMD or NVCR?
By revenue growth (latest reported year), Merit Medical Systems, Inc.
(MMSI) is pulling ahead at 11. 7% versus -24. 2% for Retractable Technologies, Inc. (RVP). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -66. 7% for Retractable Technologies, Inc.. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RVP or NNBR or MMSI or UTMD or NVCR?
Utah Medical Products, Inc.
(UTMD) is the more profitable company, earning 29. 3% net margin versus -36. 0% for Retractable Technologies, Inc. — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus -63. 9% for RVP. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RVP or NNBR or MMSI or UTMD or NVCR more undervalued right now?
On forward earnings alone, Utah Medical Products, Inc.
(UTMD) trades at 10. 4x forward P/E versus 43. 6x for NN, Inc. — 33. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — RVP or NNBR or MMSI or UTMD or NVCR?
In this comparison, UTMD (1.
9% yield), RVP (1. 1% yield) pay a dividend. NNBR, MMSI, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is RVP or NNBR or MMSI or UTMD or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Utah Medical Products, Inc.
(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). NN, Inc. (NNBR) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +19. 1%, NNBR: -75. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RVP and NNBR and MMSI and UTMD and NVCR?
These companies operate in different sectors (RVP (Healthcare) and NNBR (Industrials) and MMSI (Healthcare) and UTMD (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
RVP, UTMD pay a dividend while NNBR, MMSI, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.